{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:31:02Z","timestamp":1792089062707,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Reactivation of hepatitis B virus (HBV), characterized by increased levels of serum HBV DNA, abnormal liver function and hepatic failure, is a frequent complication of immunosuppressive therapy and chemotherapy in patients with HBV infection. However, reactivation of occult HBV infection with immunosuppressive therapy or chemotherapy is rare.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 77-year-old man was diagnosed with nephrotic syndrome and IgM nephropathy with unclear pathogenesis. Liver function was normal, HBV-related serum markers were negative and HBV DNA titer was below the upper limits of normal. Two months following the start of prednisone therapy for his nephrotic syndrome, laboratory tests revealed a substantial increase in serum transaminase levels (ALT: 490 IU\/L; AST: 149 IU\/L) and an elevation of HBV DNA level (3.42\u00d710<jats:sup>6<\/jats:sup> copies\/ml). We tested stored kidney tissue for HBsAg and HBcAg using immunohistochemistry and found the sample to be HBcAg positive, allowing us to confirm the etiology of nephropathy as an occult HBV infection. The cause of the hepatitis was thought to be HBV reactivation, so we immediately administered lamivudine. One month after the initiation of daily lamivudine treatment, laboratory tests revealed that serum levels of transaminases had improved (ALT: 35 IU\/L; AST: 17 IU\/L). Patient examination one year later showed that HBeAg had decreased with a concomitant increase of HBeAb, the quantity of HBV DNA was undetectable, and liver function and renal function had stabilized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This is the first report describing HBV reactivation in an occult HBV infection patient treated with oral prednisone for nephrotic syndrome. HBV-associated antigen should be regularly tested for in patients with unknown etiological glomerulonephritis in areas with high HBV viral popular and even in those with no clinical evidence for diagnosis of HBV.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-13-394","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T06:14:52Z","timestamp":1377584092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review"],"prefix":"10.1186","volume":"13","author":[{"given":"Wenjun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaomin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"issue":"4","key":"2595_CR1","first-page":"193","volume":"97","author":"MR Knieser","year":"1974","unstructured":"Knieser MR, Jenis EH, Lowenthal DT, Bancroft WH, Burns W, Shalhoub R: Pathogenesis of renal disease associated with viral hepatitis. Arch Pathol. 1974, 97 (4): 193-200.","journal-title":"Arch Pathol"},{"issue":"7879","key":"2595_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(74)92012-1","volume":"2","author":"WJ Brzosko","year":"1974","unstructured":"Brzosko WJ, Krawczynski K, Nazarewicz T, Morzycka M, Nowoslawski A: Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet. 1974, 2 (7879): 477-482.","journal-title":"Lancet"},{"issue":"1","key":"2595_CR3","first-page":"76","volume":"10","author":"M Levy","year":"1996","unstructured":"Levy M, Gagnadoux MF: Membranous nephropathy following perinatal transmission of hepatitis B virus infection\u2014long-term follow-up study. Pediatr Nephrol. 1996, 10 (1): 76-78.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"2595_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/adc.58.7.488","volume":"58","author":"J Wiggelinkhuizen","year":"1983","unstructured":"Wiggelinkhuizen J, Sinclair-Smith C, Stannard LM, Smuts H: Hepatitis B virus associated membranous glomerulonephritis. Arch Dis Child. 1983, 58 (7): 488-496. 10.1136\/adc.58.7.488.","journal-title":"Arch Dis Child"},{"issue":"4","key":"2595_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/00005792-199007000-00002","volume":"69","author":"VS Venkataseshan","year":"1990","unstructured":"Venkataseshan VS, Lieberman K, Kim DU, et al: Hepatitis-B-associated glomerulonephritis: pathology,pathogenesis, and clinical course. Medicine (Baltimore). 1990, 69 (4): 200-216.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2595_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.1995.27","volume":"47","author":"CY Lin","year":"1995","unstructured":"Lin CY: Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alphainterferon. Kidney Int. 1995, 47 (1): 225-230. 10.1038\/ki.1995.27.","journal-title":"Kidney Int"},{"issue":"1","key":"2595_CR7","first-page":"3","volume":"92","author":"RA Willson","year":"1997","unstructured":"Willson RA: Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol. 1997, 92 (1): 3-17.","journal-title":"Am J Gastroenterol"},{"key":"2595_CR8","first-page":"92","volume":"14","author":"LJ Fang","year":"1996","unstructured":"Fang LJ, Sheng FY, Guo YQ, et al: Hepatitis B virus associated nephritis in adults and children. ZhonghuaChuanranbingxueZazhi. 1996, 14: 92-95.","journal-title":"ZhonghuaChuanranbingxueZazhi"},{"key":"2595_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","volume":"46","author":"G Raimondo","year":"2007","unstructured":"Raimondo G, Pollicino T, Cacciola I, Squadrito G: Occult hepatitis B virus infection. J Hepatol. 2007, 46: 160-170. 10.1016\/j.jhep.2006.10.007.","journal-title":"J Hepatol"},{"key":"2595_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jmv.20119","volume":"73","author":"D Jeantet","year":"2004","unstructured":"Jeantet D, Chemin I, Mandrand B, Tran A, Zoulim F, Merle P, Trepo C, Kay A: Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol. 2004, 73: 508-515. 10.1002\/jmv.20119.","journal-title":"J Med Virol"},{"key":"2595_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.20383","volume":"40","author":"RS Garfein","year":"2004","unstructured":"Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, Groom AV, Nainan OV, Murphy JS, Bell BP: Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology. 2004, 40: 865-873.","journal-title":"Hepatology"},{"key":"2595_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-9071(199905)58:1<1::AID-JMV1>3.0.CO;2-M","volume":"58","author":"DR Petzold","year":"1999","unstructured":"Petzold DR, Tautz B, Wolf F, Drescher J: Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially. J Med Virol. 1999, 58: 1-10. 10.1002\/(SICI)1096-9071(199905)58:1<1::AID-JMV1>3.0.CO;2-M.","journal-title":"J Med Virol"},{"key":"2595_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/ki.2009.392","volume":"77","author":"XJ Zhou","year":"2010","unstructured":"Zhou XJ, Laszik Z, Nadasdy T, D\u2019Agati VD, Silva FG: Silva\u2019s diadnostic renal pathology. Kidney International. 2010, 77: 939-940. 10.1038\/ki.2009.392.","journal-title":"Kidney International"},{"key":"2595_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJM199106133242405","volume":"324","author":"TJ Liang","year":"1991","unstructured":"Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E: A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med. 1991, 324: 1705-1709. 10.1056\/NEJM199106133242405.","journal-title":"N Engl J Med"},{"key":"2595_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008, 148: 519-528. 10.7326\/0003-4819-148-7-200804010-00008.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2595_CR16","first-page":"229","volume":"29","author":"KN Lai","year":"1988","unstructured":"Lai KN, Lai FM, Tam JS, Vallance-Owen J: Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol. 1988, 29 (5): 229-234.","journal-title":"Clin Nephrol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-394\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:58:20Z","timestamp":1630544300000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-394","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]},"assertion":[{"value":"28 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"394"}}